Cargando…
A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome
Anti-phospholipid Antibody Syndrome or Hugh's syndrome is a heterogeneous disorder, first fully described in 1980s. The syndrome is caused by the presence of specific antibodies against phospholipid binding plasma proteins in the serum of the patient, with or without underlying autoimmune disea...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Journal of the Nepal Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827589/ https://www.ncbi.nlm.nih.gov/pubmed/31477950 http://dx.doi.org/10.31729/jnma.4226 |
_version_ | 1784647665999413248 |
---|---|
author | Vaidya, Binit Nakarmi, Shweta Joshi, Rakshya Baral, Rikesh |
author_facet | Vaidya, Binit Nakarmi, Shweta Joshi, Rakshya Baral, Rikesh |
author_sort | Vaidya, Binit |
collection | PubMed |
description | Anti-phospholipid Antibody Syndrome or Hugh's syndrome is a heterogeneous disorder, first fully described in 1980s. The syndrome is caused by the presence of specific antibodies against phospholipid binding plasma proteins in the serum of the patient, with or without underlying autoimmune diseases, that causes prolongation of tests of coagulation. High index of clinical suspicion is required for the diagnosis of Anti-phospholipid Antibody Syndrome. Stroke or myocardial infarction in young, unprovoked recurrent deep vein thrombosis and recurrent pregnancy loss are typical scenarios where Anti-phospholipid Antibody Syndrome should be suspected. Presence of non-criteria manifestations like livedo reticularis, skin ulcers, nephropathy, valvular heart disease and thrombocytopenia adds to the diagnostic clue for the presence of Anti-phospholipid Antibody Syndrome. Treatment of Anti-phospholipid Antibody Syndrome has preventive and therapeutic aspects that usually focus on thrombotic and obstetric manifestations of the disease. Therapeutic anti-coagulation with heparin followed by warfarin is required for patients presenting with acute thrombosis. Those with venous thrombosis are given moderate intensity warfarin (International Normalized Ratio, 2–3), whereas those with arterial thrombosis or recurrent venous thrombosis even on warfarin are treated with high intensity warfarin (International Normalized Ratio, 3–4). Similarly, anticoagulation with heparin is advised in patients with obstetric Anti-phospholipid Antibody Syndrome throughout pregnancy and up to six weeks postpartum. Treatment recommendations are still not clear for asymptomatic Anti-phospholipid Antibody Syndrome positive patients and in those with non-criteria manifestations of the disease. Steroids, intravenous immunoglobulin and immunosuppressant are reported to be effective in severe cases of catastrophic antiphospholipid syndrome characterized by rapid small vessel thrombotic involvement of multiple organ systems. Studies are evaluating the efficacy of direct thrombin inhibitors in the management of refractory cases. |
format | Online Article Text |
id | pubmed-8827589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Journal of the Nepal Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-88275892022-03-01 A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome Vaidya, Binit Nakarmi, Shweta Joshi, Rakshya Baral, Rikesh JNMA J Nepal Med Assoc Review Article Anti-phospholipid Antibody Syndrome or Hugh's syndrome is a heterogeneous disorder, first fully described in 1980s. The syndrome is caused by the presence of specific antibodies against phospholipid binding plasma proteins in the serum of the patient, with or without underlying autoimmune diseases, that causes prolongation of tests of coagulation. High index of clinical suspicion is required for the diagnosis of Anti-phospholipid Antibody Syndrome. Stroke or myocardial infarction in young, unprovoked recurrent deep vein thrombosis and recurrent pregnancy loss are typical scenarios where Anti-phospholipid Antibody Syndrome should be suspected. Presence of non-criteria manifestations like livedo reticularis, skin ulcers, nephropathy, valvular heart disease and thrombocytopenia adds to the diagnostic clue for the presence of Anti-phospholipid Antibody Syndrome. Treatment of Anti-phospholipid Antibody Syndrome has preventive and therapeutic aspects that usually focus on thrombotic and obstetric manifestations of the disease. Therapeutic anti-coagulation with heparin followed by warfarin is required for patients presenting with acute thrombosis. Those with venous thrombosis are given moderate intensity warfarin (International Normalized Ratio, 2–3), whereas those with arterial thrombosis or recurrent venous thrombosis even on warfarin are treated with high intensity warfarin (International Normalized Ratio, 3–4). Similarly, anticoagulation with heparin is advised in patients with obstetric Anti-phospholipid Antibody Syndrome throughout pregnancy and up to six weeks postpartum. Treatment recommendations are still not clear for asymptomatic Anti-phospholipid Antibody Syndrome positive patients and in those with non-criteria manifestations of the disease. Steroids, intravenous immunoglobulin and immunosuppressant are reported to be effective in severe cases of catastrophic antiphospholipid syndrome characterized by rapid small vessel thrombotic involvement of multiple organ systems. Studies are evaluating the efficacy of direct thrombin inhibitors in the management of refractory cases. Journal of the Nepal Medical Association 2019-04 2019-04-30 /pmc/articles/PMC8827589/ /pubmed/31477950 http://dx.doi.org/10.31729/jnma.4226 Text en © The Author(s) 2018. https://creativecommons.org/licenses/by/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Vaidya, Binit Nakarmi, Shweta Joshi, Rakshya Baral, Rikesh A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome |
title | A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome |
title_full | A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome |
title_fullStr | A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome |
title_full_unstemmed | A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome |
title_short | A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome |
title_sort | simplified understanding of the black swan: anti-phospholipid antibody syndrome |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827589/ https://www.ncbi.nlm.nih.gov/pubmed/31477950 http://dx.doi.org/10.31729/jnma.4226 |
work_keys_str_mv | AT vaidyabinit asimplifiedunderstandingoftheblackswanantiphospholipidantibodysyndrome AT nakarmishweta asimplifiedunderstandingoftheblackswanantiphospholipidantibodysyndrome AT joshirakshya asimplifiedunderstandingoftheblackswanantiphospholipidantibodysyndrome AT baralrikesh asimplifiedunderstandingoftheblackswanantiphospholipidantibodysyndrome AT vaidyabinit simplifiedunderstandingoftheblackswanantiphospholipidantibodysyndrome AT nakarmishweta simplifiedunderstandingoftheblackswanantiphospholipidantibodysyndrome AT joshirakshya simplifiedunderstandingoftheblackswanantiphospholipidantibodysyndrome AT baralrikesh simplifiedunderstandingoftheblackswanantiphospholipidantibodysyndrome |